Overview of Pfizer’s medication portfolio
Pfizer develops and commercializes medications across vaccines, biologics, and small-molecule drugs spanning infectious disease, oncology, immunology, and rare diseases. Notable vaccines include Comirnaty (COVID-19), Prevnar 20 (pneumococcal), and Trumenba (meningococcal B); key biologics include Enbrel (etanercept), Xeljanz (tofacitinib), and Ibrance (palbociclib) for oncology; and the portfolio includes specialized therapies for rare genetic conditions. This profile focuses on verified, widely adopted medicines and established assets rather than experimental compounds.
Therapeutic area: infectious diseases
Vaccines
- Comirnaty (COVID-19 mRNA vaccine) — authorized in multiple regions for prevention of COVID-19.
- Pneumococcal vaccines (Prevnar 13, Prevnar 20, Pneumovax 23) — prevention of pneumococcal disease.
- Trumenba and Bexsero — meningococcal B vaccines.
- Typhoid conjugate vaccine and oral typhoid vaccine — prevention of typhoid fever.
Antibiotics and antivirals
- Xeljanz (tofacitinib) — a small-molecule JAK inhibitor investigated for certain viral conditions in research contexts, primarily a small-molecule option for inflammatory conditions.
| Medication (brand/generic) | Therapeutic area | Verification status | Notes |
|---|---|---|---|
| Comirnaty (COVID-19 vaccine) | Infectious disease (viral) | Verified; widely authorized | mRNA vaccine; multiple formulations authorized |
| Prevnar 20 (pneumococcal polysaccharide conjugate) | Infectious disease (bacterial) | Verified; established use | CDC-recommended for older adults and certain younger patients |
| Xeljanz (tofacitinib) | Immunology/oncology (small molecule) | Verified; approved in many regions | JAK inhibitor; used for rheumatoid arthritis and related conditions, with ongoing research into infectious disease adjunctive contexts |
Therapeutic area: oncology
- Ibrance (palbociclib) — CDK4/6 inhibitor for hormone receptor-positive breast cancer.
- Xalkori (crizotinib) — ALK/ROS1 inhibitor for non-small cell lung cancer (NSCLC).
- Larxene (nelarabine) — indicated for T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma.
Collaborations and access considerations
Pfizer partners with multiple organizations to ensure appropriate use and patient support for oncology therapies; label indications, dosing, and monitoring are determined by regulatory authorities and evolve with new evidence.
| Medication (brand/generic) | Therapeutic area | Verification status | Notes |
|---|---|---|---|
| Ibrance (palbociclib) | Oncology (breast cancer) | Verified; approved globally | CDK4/6 inhibitor; requires monitoring for neutropenia |
| Xalkori (crizotinib) | Oncology (NSCLC) | Verified; approved in many regions | Targeted therapy for ALK/ROS1-positive NSCLC |
| Larxene (nelarabine) | Oncology (leukemia/lymphoma) | Verified; approved in multiple regions | Used for T-ALL and T-cell lymphoblastic lymphoma |
Therapeutic area: immunology and inflammatory conditions
- Enbrel (etanercept) — a TNF inhibitor for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis.
- Xeljanz (tofacitinib) — a small-molecule JAK inhibitor for rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.
Safety and prescribing context
Biologics and small-molecule modifiers require careful patient selection and monitoring for infections and other adverse effects. Prescribing decisions are individualized based on comorbidities, prior therapies, and regulatory guidance.
| Medication (brand/generic) | Therapeutic area | Verification status | Notes |
|---|---|---|---|
| Enbrel (etanercept) | Immunology (inflammatory) | Verified; widely used TNF inhibitor | Administered by subcutaneous injection; regular monitoring recommended |
| Xeljanz (tofacitinib) | Immunology (inflammatory) | Verified; approved in many regions | Small-molecule JAK inhibitor; boxed warnings include thrombosis and malignancy risk |
Therapeutic area: rare diseases and specialized therapies
Pfizer’s rare disease portfolio includes therapies tailored to specific genetic and metabolic conditions. These treatments often require specialized care and long-term monitoring; access may involve managed policies and patient support programs.
Considerations for patients and clinicians
- Genetic counseling and confirmatory testing before initiation where applicable.
- Ongoing registries and data collection to support long-term outcomes.
- Coordination with specialty pharmacies for complex therapies.
| Medication / Asset class | Therapeutic area | Verification status | Notes |
|---|---|---|---|
| Onpattro (patisiran) — outside Pfizer; example context for inherited ATTR | Rare disease (ATTR amyloidosis) | Not Pfizer; illustrative only | Highlights class considerations for rare diseases |
| Pfizer rare disease assets (specific names vary by region) | Varies | Under development or region-specific; consult official pipeline | Individual programs are condition-dependent and evolve |
Pipeline and emerging assets: staying informed
Pfizer maintains an evolving pipeline across vaccines, oncology, rare diseases, and inflammatory conditions. Clinical trial phases and regulatory statuses change as programs advance; stakeholders should reference Pfizer’s official pipeline resources and regulatory filings for the most current information. This overview covers established medicines with enduring relevance rather than transient developmental candidates.
Safety, access, and prescribing guidance
The use of Pfizer medications is governed by regional regulatory authorizations, formulary placements, and clinical guidelines. Key considerations include:
- Adherence to labeling, indications, and dosing adjustments for renal or hepatic impairment.
- Monitoring for immune-mediated adverse events with biologics and small-molecule modifiers.
- Integration with multidisciplinary care, including specialty pharmacy and nursing support.
For personalized medical decisions, consult a qualified healthcare professional and reference the most current local product information.
FAQ
Reader questions
Which Pfizer medication is most widely used?
Comirnaty (COVID-19 vaccine) and Prevnar-series pneumococcal vaccines represent high-volume preventive assets; Enbrel and Xeljanz are among the widely prescribed therapies in immunology and oncology, respectively. Usage varies by region and patient population.
Are all Pfizer medications available globally?
Availability differs by country due to regulatory approvals, market access agreements, and local formularies. Patients should check with their healthcare provider or local health authority for region-specific options.
How are Pfizer medications named and branded?
Pfizer assigns both a proprietary (brand) name and, where applicable, an International Nonproprietary Name (INN) or established generic name. Confusing labels can occur when multiple assets share similar stems (e.g., -cillin for certain antibiotics, -cept for TNF inhibitors).